Trastuzumab Deruxtecan
DS8201-801
Phase 1 small_molecule active
Quick answer
Trastuzumab Deruxtecan for Recurrent or Metastatic Solid Tumors is a Phase 1 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo
- Indication
- Recurrent or Metastatic Solid Tumors
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active